Dane Ediger
Overview
Explore the profile of Dane Ediger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Celebi Sozener Z, Oguzulgen I, Ozalp Ates F, Baccioglu A, Argun Baris S, Ediger D, et al.
J Asthma
. 2025 Feb;
:1-11.
PMID: 39932533
Objective: The obese-asthma phenotype has gradually increased in the last few years. We aimed to assess the differences between obese and non-obese patients with asthma. Methods: This research is a...
2.
Arslan B, Turk M, Hayme S, Aydin O, Gokmen D, Koycu Buhari G, et al.
Clin Transl Allergy
. 2025 Jan;
15(1):e70018.
PMID: 39865387
Background: Asthma is one of the most common causes of chronic respiratory disease, and countries with low socioeconomic status have both a high prevalence of asthma and asthma-related death. Objective:...
3.
Beyaz S, Erdinc M, Hayme S, Aslan A, Aydin O, Gokmen D, et al.
Allergol Immunopathol (Madr)
. 2025 Jan;
53(1):12-25.
PMID: 39786871
Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This...
4.
Gemicioglu B, Gokmen D, Can A, Sevinc C, Oguzulgen I, Soyyigit S, et al.
Respir Med
. 2024 Dec;
236:107883.
PMID: 39617354
Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims...
5.
Damadoglu E, Aktas O, Gemicioglu B, Yilmaz N, Bozkus F, Ayhan V, et al.
Turk J Med Sci
. 2024 May;
54(1):309-315.
PMID: 38812643
Background/aim: Characteristics of asthma in the elderly population is not well-known. The aim of the present study was to evaluate asthma in the elderly population, to compare disease characteristics between...
6.
Development and validation of a simple risk scoring system for a COVID-19 diagnostic prediction mode
Aydin Guclu O, Ursavas A, Ocakoglu G, Demirdogen E, Acet Ozturk N, Omer Topcu D, et al.
Tuberk Toraks
. 2023 Dec;
71(4):325-334.
PMID: 38152003
Introduction: In a resource-constrained situation, a clinical risk stratification system can assist in identifying individuals who are at higher risk and should be tested for COVID-19. This study aims to...
7.
Celik G, Aydin O, Damadoglu E, Baccioglu A, Kepil Ozdemir S, Bavbek S, et al.
Thorac Res Pract
. 2023 Nov;
24(6):309-324.
PMID: 37909830
Introduction of inhaled corticosteroids (ICS) has been the cornerstone of the long-term management of asthma. ICSs either alone or in combination with long-acting beta-2 agonists have been shown to be...
8.
Cerci P, Kendirlinan R, Buyukozturk S, Gelincik A, Unal D, Demir S, et al.
Allergol Immunopathol (Madr)
. 2023 Sep;
51(5):84-92.
PMID: 37695234
Background: Hypersensitivity reactions (HSRs) to nonsteroidal anti-inflammatory drugs (NSAIDs) are a significant clinical issue. Several classifications have been proposed to categorize these reactions, including the current European Academy of Allergy...
9.
Celik G, Aydin O, Gokmen D, Koycu Buhari G, Celebi Sozener Z, Gemicioglu B, et al.
J Asthma
. 2023 Apr;
60(11):1973-1986.
PMID: 37096963
Introduction: National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry...
10.
Ediger D, Gunaydin F, Erbay M, Pekbak G
Tuberk Toraks
. 2023 Mar;
71(1):24-33.
PMID: 36912406
Introduction: Omalizumab, a humanized monoclonal anti-IgE antibody, has largely demonstrated its efficacy in severe allergic asthma. There are limited data about the effectiveness of omalizumab in patients with non-atopic severe...